EyePoint, Inc. (EYPT)
12.34
-0.90
(-6.80%)
USD |
NASDAQ |
May 15, 16:00
12.40
+0.06
(+0.49%)
Pre-Market: 08:27
EyePoint Research and Development Expense (Quarterly) : 72.15M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Ocular Therapeutix, Inc. | 66.21M |
| Merck & Co., Inc. | 11.98B |
| Bristol Myers Squibb Co. | 2.238B |
| Arvinas, Inc. | 60.00M |
| Corcept Therapeutics, Inc. | 66.26M |